Palace: Duterte can choose vaccine brand because ‘he’s the President, over 70 yrs. old’ | Inquirer News

Palace: Duterte can choose vaccine brand because ‘he’s the President, over 70 yrs. old’

By: - Reporter / @KAguilarINQ
/ 06:25 PM March 04, 2021

MANILA, Philippines — President Rodrigo Duterte gets to choose which COVID-19 vaccine brand to receive simply because of his position as chief executive and his age, Malacañang said Thursday.

“Well you know, I think the President is the President and because he is over 70 years old ‘no,” presidential spokesperson Harry Roque said when asked why Duterte may choose his preferred vaccine brand. Duterte is turning 77 years old this month.

Article continues after this advertisement

Roque has said Duterte prefers to get the vaccine developed by China state-owned Sinopharm and is even willing to wait for its vaccine to get an emergency use authorization before receiving it.

FEATURED STORIES

But now that the AstraZeneca vaccine is arriving in the country, Roque said he would ask Duterte if he wants to be vaccinated with this instead.

“I will ask if he will consider AstraZeneca because in other countries ‘no, wala namang limitation on the use of AstraZeneca,” Roque said.

Article continues after this advertisement

When AstraZeneca’s COVID-19 vaccine secured an EUA in the Philippines, the Food and Drug Administration said it can be given to people 18 years old and older unlike the Sinovac vaccine recommended only for those aged 18 to 59.

The Philippines will receive Thursday night some 487,200 doses of AstraZeneca vaccines from the World Health Organization-led COVAX facility.

JE
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: COVID-19 Vaccine, Malacañang, Palace, Rodrigo Duterte, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.